Nymox Pharmaceutical Corp financial data

Symbol
NYMXF on OTC
Industry
In Vitro & In Vivo Diagnostic Substances
Location
9900 Cavendish Blvd., Suite 306, St. Laurent, Quebec Canada, Quebec, Canada
Fiscal year end
December 31
Latest financial report
6-K - Q3 2023 - Nov 15, 2023

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.5M shares +5.81%

Income Statement

Label TTM Value / Value Unit Change %
Research And Development Expense -288K USD -104%
General And Administrative Expense 353K USD -39.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets 669K USD -78.7%
Liabilities 2.57M USD +8.57%

Popular Metrics

Label TTM Value / Value Unit Change %
Interest Expense 22K USD +120%